Clinical Trials · NCT03017313
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 510
- Start date
- Jul 2017
- Locations
- 27 sites, Spain
- Primary endpoint
- Percentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation).